28 completed, 3 terminated, 1 active not recruiting. 32 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 32 | Completed 28, Terminated 3, Active not recruiting 1 |
| Phase 1 | 4 | Completed 4 |
Follow cixutumumab: new trials by email Literature Review of cixutumumab trials Research Report on cixutumumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Cixutumumab, Laboratory Biomarker Analysis, Temsirolimus - Childhood Alveolar Soft Part Sarcoma, Childhood Angiosarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 46 | 2012-06-18 | 2018-12-11 |
| Preoperative Treatment With Cetuximab and/or IMC-A12 Cetuximab, IMC-A12, Surgical tumor resection - Head and Neck Squamous Cell Carcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 16 | 2011-10-17 | 2020-03-19 |
| Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye Cixutumumab, Laboratory biomarker analysis - Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size | Phase 2 | Completed | National Cancer Institute (NCI) | 18 | 2011-08-01 | 2020-02-19 |
| BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer Carboplatin, Pemetrexed, Bevacizumab - Lung Cancer | Phase 2 | Completed | M.D. Anderson Cancer Center | 64 | 2011-05-17 | 2019-05-15 |
| A Study in Non-Small Cell Lung Cancer Pemetrexed, Cisplatin, Cixutumumab - Non-Small-Cell Lung Carcinoma | Phase 2 | Completed | Eli Lilly and Company | 172 | 2011-04-01 | 2019-09-20 |
| Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer Bicalutamide, Cixutumumab, Goserelin Acetate - Prostate Adenocarcinoma, Recurrent Prostate Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 211 | 2010-12-01 | 2018-02-26 |
| Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer Cixutumumab, Laboratory Biomarker Analysis, Paclitaxel - Metastatic Esophageal Adenocarcinoma, Metastatic Esophageal Squamous Cell Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 94 | 2010-09-21 | 2026-09-10 |
| Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy IMC-A12 - Pleural Mesothelioma, Peritoneal Mesothelioma | Phase 2 | Completed | National Cancer Institute (NCI) | 20 | 2010-06-02 | 2018-04-10 |
| Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer Bevacizumab, Carboplatin, Cixutumumab - Large Cell Lung Carcinoma, Lung Adenocarcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 175 | 2010-03-01 | 2018-06-06 |
| Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma Cixutumumab, Cyclophosphamide, Dactinomycin - Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 175 | 2010-01-01 | 2017-08-29 |
| Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma Cixutumumab, Laboratory Biomarker Analysis, Temsirolimus - Metastatic Osteosarcoma, Recurrent Adult Soft Tissue Sarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 178 | 2009-11-01 | 2015-07-30 |
| Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer Cixutumumab, Diagnostic Laboratory Biomarker Analysis, Temsirolimus - Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 16 | 2009-10-01 | 2019-06-17 |
| Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer cixutumumab, carboplatin, paclitaxel - Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 140 | 2009-09-01 | 2014-09-26 |
| A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage Cisplatin, Cixutumumab, Etoposide - Extensive Stage Small Cell Lung Carcinoma, Recurrent Small Cell Lung Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 168 | 2009-07-16 | 2026-06-24 |
| A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab Cetuximab, Irinotecan, IMC-A12 (cixutumumab) - Colon Cancer, Rectal Cancer | Phase 2 | Terminated | Eli Lilly and Company | 4 | 2009-05-01 | 2018-07-02 |
| A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg), IMC-A12 (cixutumumab) - 20 mg/kg, Sorafenib - Hepatocellular Carcinoma | Phase 2 | Completed | Eli Lilly and Company | 47 | 2009-05-01 | 2018-06-04 |
| A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before Gemcitabine, Cisplatin, IMC-A12 (cixutumumab) - Non-Small Cell Lung Cancer | Phase 2 | Completed | Eli Lilly and Company | 64 | 2009-03-01 | 2018-06-01 |
| A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer Cixutumumab, depot octreotide - Carcinoma, Neuroendocrine Tumors | Phase 2 | Completed | Eli Lilly and Company | 43 | 2009-02-01 | 2019-09-20 |
| Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors cixutumumab, laboratory biomarker analysis - Adult Rhabdomyosarcoma, Adult Synovial Sarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 116 | 2009-01-01 | 2015-03-30 |
| IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery IMC-A12, mitotane - Recurrent Adrenocortical Carcinoma, Stage III Adrenocortical Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 20 | 2008-12-01 | 2014-04-29 |
Showing 20 of 32. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (6) · Prostatic Neoplasms (5) · Sarcoma (5) · Rhabdomyosarcoma (4) · Breast Neoplasms (3) · Neoplasms (3) · Osteosarcoma (3) · Adrenocortical Carcinoma (2) · Carcinoma, Hepatocellular (2) · Colorectal Neoplasms (2) · Head and Neck Neoplasms (2) · Lung Neoplasms (2) · Neoplasm Metastasis (2) · Neuroectodermal Tumors, Primitive, Peripheral (2) · Sarcoma, Ewing (2)
National Cancer Institute (NCI) (18) · Eli Lilly and Company (11) · M.D. Anderson Cancer Center (2) · University of Washington (1)
United States (32) · Canada (6) · Australia (2) · Belgium (2) · France (2) · Germany (2) · Netherlands (2) · Spain (2) · Argentina (1) · Brazil (1) · Israel (1) · Italy (1) · New Zealand (1) · Poland (1) · Turkey (Türkiye) (1)
Brenda Weigel, MD (1) · Bruce Montgomery, M.D. (1) · Chandra Belani (1) · Cynthia Ma (1) · Dana Rathkopf (1) · David Camidge (1) · Evan Yu (1) · Gary Hammer (1) · George Simon, MD (1) · Ghassan Abou-Alfa (1) · James P Dean, M.D., Ph.D. (1) · John M Corman, MD (1)
PMID 22682017, PMID 23477833, PMID 23533230, PMID 25847934, PMID 26082390, PMID 28950351, PMID 33852121, PMID 37104870
U10CA021115 (4), P30CA008748 (3), U10CA098543 (3), U10CA180820 (3), N01CM00038 (2), N01CM00071 (2), N01CM00099 (2), N01CM00100 (2), N01CM62201 (2), N01CM62205 (2), N01CM62207 (2), N01CM62209 (2), U10CA025224 (2), U10CA032102 (2), U10CA180821 (2)